Double	B:C1511667
strand	I:C1511667
break	I:C1511667
induction	O
and	O
kinetics	O
indicate	O
preserved	O
hypersensitivity	O
in	O
keratinocytes	O
to	O
subtherapeutic	O
doses	O
for	O
7	O
weeks	O
of	O
radiotherapy	O
.	O

Double	O
strand	I:C1511667
break	I:C1511667
induction	O
and	O
kinetics	O
indicate	O
preserved	O
hypersensitivity	B:C0020517
in	O
keratinocytes	O
to	O
subtherapeutic	O
doses	O
for	O
7	O
weeks	O
of	O
radiotherapy	O
.	O

Double	O
strand	I:C1511667
break	I:C1511667
induction	O
and	O
kinetics	O
indicate	O
preserved	O
hypersensitivity	O
in	O
keratinocytes	B:C0022567
to	O
subtherapeutic	O
doses	O
for	O
7	O
weeks	O
of	O
radiotherapy	O
.	O

Double	O
strand	I:C1511667
break	I:C1511667
induction	O
and	O
kinetics	O
indicate	O
preserved	O
hypersensitivity	O
in	O
keratinocytes	O
to	O
subtherapeutic	O
doses	O
for	O
7	O
weeks	O
of	O
radiotherapy	B:C1522449
.	O

Previously	O
we	O
reported	O
that	O
hyper	O
-	O
radiosensitivity	O
(	O
HRS	O
)	O
was	O
evidenced	O
by	O
quantifying	O
DNA	B:C3159064
double	I:C3159064
strand	I:C3159064
break	I:C3159064
(	I:C3159064
DSB	I:C3159064
)	I:C3159064
foci	I:C3159064
in	O
epidermis	O
biopsies	O
collected	O
after	O
delivering	O
radiotherapeutic	O
one	O
and	O
five	O
dose	O
fractions	O
.	O

Previously	O
we	O
reported	O
that	O
hyper	O
-	O
radiosensitivity	O
(	O
HRS	O
)	O
was	O
evidenced	O
by	O
quantifying	O
DNA	O
double	I:C3159064
strand	I:C3159064
break	I:C3159064
(	I:C3159064
DSB	I:C3159064
)	I:C3159064
foci	I:C3159064
in	O
epidermis	B:C0014520
biopsies	O
collected	O
after	O
delivering	O
radiotherapeutic	O
one	O
and	O
five	O
dose	O
fractions	O
.	O

Previously	O
we	O
reported	O
that	O
hyper	O
-	O
radiosensitivity	O
(	O
HRS	O
)	O
was	O
evidenced	O
by	O
quantifying	O
DNA	O
double	I:C3159064
strand	I:C3159064
break	I:C3159064
(	I:C3159064
DSB	I:C3159064
)	I:C3159064
foci	I:C3159064
in	O
epidermis	O
biopsies	B:C0005558
collected	O
after	O
delivering	O
radiotherapeutic	O
one	O
and	O
five	O
dose	O
fractions	O
.	O

Previously	O
we	O
reported	O
that	O
hyper	O
-	O
radiosensitivity	O
(	O
HRS	O
)	O
was	O
evidenced	O
by	O
quantifying	O
DNA	O
double	I:C3159064
strand	I:C3159064
break	I:C3159064
(	I:C3159064
DSB	I:C3159064
)	I:C3159064
foci	I:C3159064
in	O
epidermis	O
biopsies	O
collected	O
after	O
delivering	O
radiotherapeutic	B:C0034619
one	O
and	O
five	O
dose	O
fractions	O
.	O

The	O
aim	O
of	O
this	O
study	B:C2603343
was	O
to	O
determine	O
whether	O
HRS	O
was	O
preserved	O
throughout	O
a	O
7	O
-	O
week	O
radiotherapy	O
treatment	O
,	O
and	O
also	O
to	O
examine	O
the	O
rate	O
of	O
foci	O
decline	O
and	O
foci	O
persistence	O
between	O
dose	O
fractions	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
HRS	O
was	O
preserved	O
throughout	O
a	O
7	O
-	O
week	O
radiotherapy	B:C1522449
treatment	O
,	O
and	O
also	O
to	O
examine	O
the	O
rate	O
of	O
foci	O
decline	O
and	O
foci	O
persistence	O
between	O
dose	O
fractions	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
HRS	O
was	O
preserved	O
throughout	O
a	O
7	O
-	O
week	O
radiotherapy	O
treatment	B:C0087111
,	O
and	O
also	O
to	O
examine	O
the	O
rate	O
of	O
foci	O
decline	O
and	O
foci	O
persistence	O
between	O
dose	O
fractions	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
HRS	O
was	O
preserved	O
throughout	O
a	O
7	O
-	O
week	O
radiotherapy	O
treatment	O
,	O
and	O
also	O
to	O
examine	O
the	O
rate	O
of	O
foci	B:C3159064
decline	O
and	O
foci	O
persistence	O
between	O
dose	O
fractions	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
HRS	O
was	O
preserved	O
throughout	O
a	O
7	O
-	O
week	O
radiotherapy	O
treatment	O
,	O
and	O
also	O
to	O
examine	O
the	O
rate	O
of	O
foci	O
decline	O
and	O
foci	B:C3159064
persistence	O
between	O
dose	O
fractions	O
.	O

42	O
patients	O
with	O
prostate	B:C0600139
cancer	I:C0600139
received	O
7	O
-	O
week	O
fractionated	O
radiotherapy	O
treatment	I:C1522449
(	O
radiotherapy	O
treatment	I:C1522449
)	O
with	O
daily	O
dose	O
fractions	O
of	O
0.05	O
-	O
1.10	O

42	O
patients	O
with	O
prostate	O
cancer	I:C0600139
received	O
7	O
-	O
week	O
fractionated	O
radiotherapy	B:C1522449
treatment	I:C1522449
(	O
radiotherapy	O
treatment	I:C1522449
)	O
with	O
daily	O
dose	O
fractions	O
of	O
0.05	O
-	O
1.10	O

42	O
patients	O
with	O
prostate	O
cancer	I:C0600139
received	O
7	O
-	O
week	O
fractionated	O
radiotherapy	O
treatment	I:C1522449
(	O
radiotherapy	B:C1522449
treatment	I:C1522449
)	O
with	O
daily	O
dose	O
fractions	O
of	O
0.05	O
-	O
1.10	O

Gy	O
to	O
the	O
skin	B:C1123023
.	O

Before	O
radiotherapy	B:C1522449
treatment	I:C1522449
,	O
and	O
at	O
several	O
times	O
throughout	O
treatment	O
,	O
skin	O
biopsies	I:C0150866
(	O
n=452	O
)	O
were	O
collected	O
at	O
30	O
min	O
,	O
and	O
2	O
,	O
3	O
,	O
24	O
,	O
and	O
72h	O
after	O
dose	O
fractions	O
.	O

Before	O
radiotherapy	O
treatment	I:C1522449
,	O
and	O
at	O
several	O
times	O
throughout	O
treatment	B:C0087111
,	O
skin	O
biopsies	I:C0150866
(	O
n=452	O
)	O
were	O
collected	O
at	O
30	O
min	O
,	O
and	O
2	O
,	O
3	O
,	O
24	O
,	O
and	O
72h	O
after	O
dose	O
fractions	O
.	O

Before	O
radiotherapy	O
treatment	I:C1522449
,	O
and	O
at	O
several	O
times	O
throughout	O
treatment	O
,	O
skin	B:C0150866
biopsies	I:C0150866
(	O
n=452	O
)	O
were	O
collected	O
at	O
30	O
min	O
,	O
and	O
2	O
,	O
3	O
,	O
24	O
,	O
and	O
72h	O
after	O
dose	O
fractions	O
.	O

DSB	B:C3159064
-	I:C3159064
foci	I:C3159064
markers	O
,	O
γ	O
H2AX	I:C1415406
and	O
53BP1	O
,	O
were	O
labelled	O
in	O
epidermal	O
keratinocytes	O
with	O
immunofluorescence	O
and	O
immunohistochemical	O
staining	O
.	O

DSB	O
-	I:C3159064
foci	I:C3159064
markers	B:C0012872
,	O
γ	O
H2AX	I:C1415406
and	O
53BP1	O
,	O
were	O
labelled	O
in	O
epidermal	O
keratinocytes	O
with	O
immunofluorescence	O
and	O
immunohistochemical	O
staining	O
.	O

DSB	O
-	I:C3159064
foci	I:C3159064
markers	O
,	O
γ	B:C1415406
H2AX	I:C1415406
and	O
53BP1	O
,	O
were	O
labelled	O
in	O
epidermal	O
keratinocytes	O
with	O
immunofluorescence	O
and	O
immunohistochemical	O
staining	O
.	O

DSB	O
-	I:C3159064
foci	I:C3159064
markers	O
,	O
γ	O
H2AX	I:C1415406
and	O
53BP1	B:C1420865
,	O
were	O
labelled	O
in	O
epidermal	O
keratinocytes	O
with	O
immunofluorescence	O
and	O
immunohistochemical	O
staining	O
.	O

DSB	O
-	I:C3159064
foci	I:C3159064
markers	O
,	O
γ	O
H2AX	I:C1415406
and	O
53BP1	O
,	O
were	O
labelled	O
in	O
epidermal	B:C0014520
keratinocytes	O
with	O
immunofluorescence	O
and	O
immunohistochemical	O
staining	O
.	O

DSB	O
-	I:C3159064
foci	I:C3159064
markers	O
,	O
γ	O
H2AX	I:C1415406
and	O
53BP1	O
,	O
were	O
labelled	O
in	O
epidermal	O
keratinocytes	B:C0022567
with	O
immunofluorescence	O
and	O
immunohistochemical	O
staining	O
.	O

DSB	O
-	I:C3159064
foci	I:C3159064
markers	O
,	O
γ	O
H2AX	I:C1415406
and	O
53BP1	O
,	O
were	O
labelled	O
in	O
epidermal	O
keratinocytes	O
with	O
immunofluorescence	B:C0016318
and	O
immunohistochemical	O
staining	O
.	O

Foci	O
were	O
counted	O
both	O
with	O
digital	B:C2348290
image	I:C2348290
analysis	I:C2348290
and	O
manually	O
.	O

HRS	O
in	O
keratinocytes	B:C0022567
was	O
evidenced	O
by	O
the	O
dose	O
-	O
response	O
relationships	O
of	O
DSB	O
foci	I:C3159064
,	O
observed	O
throughout	O
the	O
treatment	O
course	O
,	O
independent	O
of	O
sampling	O
time	O
and	O
quantification	O
method	O
.	O

HRS	O
in	O
keratinocytes	O
was	O
evidenced	O
by	O
the	O
dose	O
-	O
response	O
relationships	O
of	O
DSB	B:C3159064
foci	I:C3159064
,	O
observed	O
throughout	O
the	O
treatment	O
course	O
,	O
independent	O
of	O
sampling	O
time	O
and	O
quantification	O
method	O
.	O

HRS	O
in	O
keratinocytes	O
was	O
evidenced	O
by	O
the	O
dose	O
-	O
response	O
relationships	O
of	O
DSB	O
foci	I:C3159064
,	O
observed	O
throughout	O
the	O
treatment	O
course	O
,	O
independent	O
of	O
sampling	B:C0441621
time	O
and	O
quantification	O
method	O
.	O

HRS	O
in	O
keratinocytes	O
was	O
evidenced	O
by	O
the	O
dose	O
-	O
response	O
relationships	O
of	O
DSB	O
foci	I:C3159064
,	O
observed	O
throughout	O
the	O
treatment	O
course	O
,	O
independent	O
of	O
sampling	O
time	O
and	O
quantification	O
method	B:C0025663
.	O

Foci	B:C3159064
observed	O
at	O
24h	O
after	O
dose	O
fractions	O
indicated	O
considerable	O
double	O
strand	I:C1511667
break	I:C1511667
persistence	O
.	O

Foci	O
observed	O
at	O
24h	O
after	O
dose	O
fractions	O
indicated	O
considerable	O
double	B:C1511667
strand	I:C1511667
break	I:C1511667
persistence	O
.	O

Accordingly	O
,	O
foci	B:C3159064
significantly	O
accumulated	O
after	O
5	O
consecutive	O
dose	O
fractions	O
.	O

For	O
doses	O
below	O
0.3	O
Gy	O
,	O
persistent	O
foci	B:C3159064
could	O
be	O
observed	O
even	O
at	O
72h	O
after	O
damage	O
induction	O
.	O

For	O
doses	O
below	O
0.3	O
Gy	O
,	O
persistent	O
foci	O
could	O
be	O
observed	O
even	O
at	O
72h	O
after	O
damage	B:C0012860
induction	O
.	O

A	O
comparison	O
of	O
γ	B:C1415406
H2AX	I:C1415406
and	O
53BP1	O
quantifications	O
in	O
double	O
-	O
staine	O
d	O
biopsies	O
showed	O
similar	O
HRS	O
dose	O
-	O
response	O
relationships	O
.	O

A	O
comparison	O
of	O
γ	O
H2AX	I:C1415406
and	O
53BP1	B:C1420865
quantifications	O
in	O
double	O
-	O
staine	O
d	O
biopsies	O
showed	O
similar	O
HRS	O
dose	O
-	O
response	O
relationships	O
.	O

A	O
comparison	O
of	O
γ	O
H2AX	I:C1415406
and	O
53BP1	O
quantifications	O
in	O
double	O
-	O
staine	O
d	O
biopsies	B:C0005558
showed	O
similar	O
HRS	O
dose	O
-	O
response	O
relationships	O
.	O

These	O
results	O
represented	O
the	O
first	O
evidence	O
of	O
preserved	O
HRS	O
,	O
assessed	O
by	O
γ	B:C1415406
H2AX	I:C1415406
-	O
and	O
53BP1	O
-	O
labelled	O
DSB	O
foci	I:C3159064
,	O
throughout	O
a	O
7	O
-	O
week	O
treatment	O
course	O
with	O
daily	O
repeated	O
subtherapeutic	O
dose	O
fractions	O
.	O

These	O
results	O
represented	O
the	O
first	O
evidence	O
of	O
preserved	O
HRS	O
,	O
assessed	O
by	O
γ	O
H2AX	I:C1415406
-	O
and	O
53BP1	B:C1420865
-	O
labelled	O
DSB	O
foci	I:C3159064
,	O
throughout	O
a	O
7	O
-	O
week	O
treatment	O
course	O
with	O
daily	O
repeated	O
subtherapeutic	O
dose	O
fractions	O
.	O

These	O
results	O
represented	O
the	O
first	O
evidence	O
of	O
preserved	O
HRS	O
,	O
assessed	O
by	O
γ	O
H2AX	I:C1415406
-	O
and	O
53BP1	O
-	O
labelled	O
DSB	B:C3159064
foci	I:C3159064
,	O
throughout	O
a	O
7	O
-	O
week	O
treatment	O
course	O
with	O
daily	O
repeated	O
subtherapeutic	O
dose	O
fractions	O
.	O

